

IGEA announces three new board members

This press release complements today's announcement "IGEA calls extraordinary general meeting" to be viewed on <https://www.igeapharma.nl/category/press-releases/>

Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced important changes in its board of directors. As announced today by separate press release, new persons were bindingly nominated for election as non-executive directors in the board of IGEA at the upcoming extraordinary general meeting of 28 April 2021.

Coming from various economic environments, the new board members will bring years of experience and leadership to help the combined businesses of IGEA and Blue Sky Natural Resources LTD to establish market position for health prevention, pharmaceutical, nutraceutical and cosmeceutical solutions based on CBD and other high quality vegetable matrices extracts, leverage commercial capabilities and partnerships, and capitalize on the financial leverage and operational synergies to improve return on capital and achieve profitability.

The new candidates bindingly proposed for election in the general meeting include:

- Giovanna Puppo, Equity Partner at Grimaldi Studio Legale, Milan;
- Massimiliano Colella, group CEO at EVERCARE, Dubai;
- Raffaele Bertoni, Head of Debt Capital Market and Senior Portfolio Manager at GIC Gulf Investment Corporation, Kuwait City.

The CVs of Giovanna Puppo, Massimiliano Colella and Raffaele Bertoni are available on <https://www.igeapharma.nl/category/information-for-shareholders/>.

About IGEA

IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. Med-tech products focuses on selected solutions and specialties, among which dry aerosol generators for air and inanimate environmental surfaces sanitization and sterilization and air purification devices.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

Contacts

Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.com

Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.